Crossing the Goal Line; Bringing Ketamine Treatments to the Clinic

Tuesday, May 14, 2019, 2:00 pm EDT
Meet the Scientist - May 2019

The discovery and development of ketamine and now esketamine as rapidly acting antidepressants has been one of the major advances in the treatment of mood disorders in the past five decades. This Webinar will provide a brief history of the discovery and development process and will provide an overview of the various clinical trials completed to date. Discussion will focus on addressing clinically relevant questions related to the use of this exciting new treatment approach and the potential benefits this drug can offer to those with treatment-resistant depression.

Please use #BBRFWebinar when sharing or posting about our Meet the Scientist Webinars on social media.

Sign up for other upcoming webinars.

View past webinar recordings.

Presented by 
Gerard Sanacora, M.D., Ph.D.
Gerard Sanacora, M.D., Ph.D.
Yale School of Medicine

Professor of Psychiatry

Director, Yale Depression Research Program

Co-Director, Yale New Haven Hospital Interventional Psychiatry Service

Scientific Council Member (Joined 2015)

2014 Distinguished Investigator Grant

2007 Independent Investigator Grant

2001, 1999 Young Investigator Grant

Dr. Sanacora completed his Ph.D. in Physiology and Biophysics (1992) and his M.D. (1994) at the State University New York at Stony Brook. He then completed the Clinical Neuroscientist Training Program Residency and the Neuroimaging Scientist Training Program Fellowship at Yale. He is currently a Professor of Psychiatry at Yale and the Director of the Yale Depression Research Program. His work has concentrated largely on elucidating the pathophysiological mechanisms associated with mood and other neuropsychiatric disorders, and using this information to guide future treatment development. His basic science laboratory explores the effects of chronic stress on brain function, and examines the molecular, cellular and behavioral effects of newly developed treatment strategies. His clinical laboratory employs novel imaging methodologies to investigate the pathophysiology of neuropsychiatric disorders and is very active in clinical trial research.

Moderated by 
Jeffrey Borenstein, M.D.
Brain & Behavior Research Foundation

President and CEO

Jeffrey Borenstein, M.D., serves as the President & CEO of the Brain & Behavior Research Foundation, the largest private funder of mental health research grants. Dr. Borenstein developed the Emmy Award-nominated public television program “Healthy Minds,” and serves as host of the series. The program, which is broadcast nationwide, focuses on topics in psychiatry in order to educate the public, reduce stigma and offer a message of hope. Dr. Borenstein also serves as Editor-in-Chief of Psychiatric News, the newspaper of the American Psychiatric Association and as an Associate Clinical Professor of Psychiatry at Columbia University College of Physicians and Surgeons.